COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS

摘要

FIELD: biotechnology.;SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for the treatment or slowing down the development of FolR1-expressing cancer in an individual. The method includes injection to an individual of a bispecific antigen-binding molecule binding to CD3 and FolR1 and an antagonist binding to the PD-1 axis.;EFFECT: obtaining compounds for the treatment of cancer.;30 cl, 40 dwg, 49 tbl, 50 ex